Tyrosinase-related protein 2-specific T cell receptor (TRP2-specific TCR) (TRP2-specific TCR)

The Tyrosinase-related protein 2-specific T cell receptor (TRP2-specific TCR) is a specialized immune receptor used by CD8+ cytotoxic T lymphocytes to identify and eliminate cells expressing TRP2, a key enzyme in melanin biosynthesis (Wang et al., 1996, J Exp Med). TRP2 is highly expressed in melanoma cells, making it a prominent tumor-associated antigen for adoptive cell therapies (Parkhurst et al., 2004, Clin Cancer Res). The TCR functions by binding to specific TRP2 peptide fragments presented by Major Histocompatibility Complex (MHC) class I molecules, such as HLA-A*02:01, on the surface of malignant cells (Noppen et al., 2000, Int J Cancer). This binding event triggers T cell activation, the release of cytotoxic granules like perforin and granzyme, and the production of pro-inflammatory cytokines (Rosenberg & Restifo, 2015, Science). In the context of biotechnology, this receptor is the focus of TCR-engineered T cell (TCR-T) therapies designed to redirect a patient's immune system against advanced melanoma (Ping et al., 2018, Front Immunol). A significant challenge in targeting this receptor is the potential for off-tumor effects, as TRP2 is also present in normal melanocytes, which can lead to autoimmune conditions like vitiligo or ocular inflammation (Overwijk et al., 1999, J Exp Med). Clinical research continues to optimize the affinity and safety of TRP2-specific TCRs to improve outcomes for patients with advanced melanoma (Singh et al., 2009, J Immunol).

Other names

TRP2-TCRDopachrome tautomerase-specific T cell receptorDCT-specific TCRTyrosinase-related protein 2-specific TCRTRP2-specific T-cell receptor

The TCR recognizes TRP2-derived peptides presented by MHC class I molecules (typically HLA-A*02:01) on tumor cells, leading to T cell activation, cytokine release, and cytotoxic destruction of the target cell (Wang et al., 1996, J Exp Med).